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Introduction
Uraemic pruritus (UP) remains a frequent and some-
times tormenting problem in patients with advanced or
end-stage renal disease [1]. Many attempts have been
made to relieve this bothersome symptom in affected
patients, however with generally limited success.
Whenever a new treatment option is reported to be
effective, some time elapses before conflicting results
are published; in the meantime, the mood of patients
and physicians changes from euphoria to disillusion-
ment. This happened with erythropoetin [2,3] and
naltrexone [4,5], the last propagated treatment
modalities in this respect.
The main obstacle in the effort to create effective
treatment modalities is the incomplete knowledge
of the underlying pathophysiological mechanisms.
Furthermore, given the great clinical heterogenicity
of UP, systematically performed studies are hard to
obtain and are therefore sparse.
Clinical features of uraemic pruritus
The intensity and spatial distribution of pruritus varies
significantly over time and some patients are affected
to a varying degree throughout the duration of their
renal disease. The intensity of UP ranges from sporadic
discomfort to complete restlessness during both the
day- and night-time. Initially, patients with UP do not
show any changes in skin appearance. Excoriation
by scratching with or without impetigo can occur as
a secondary phenomenon and rarely prurigo nodularis
or Kyrle’s disease is observed (Figure 1a–d). There
are interindividual differences in spatial distribution
of UP: 25–50% of patients with UP complain about
generalized pruritus [6,7]. In the remaining patients,
UP seems to predominantly affect the back, the
face and the shunt arm, respectively [8]. In ;25% of
patients with UP, pruritus is most severe during or
immediately after dialysis [8].
Incidence of uraemic pruritus
Whereas in the beginnings of dialysis treatment UP
was a very common problem, it appears that its inci-
dence has declined over the past 20 years. In the early
1970s, Young and co-workers reported that ;85%
[9] of patients were affected by UP. This number
decreased to 50–60% in the late 1980s [10]. A recent
investigation in Germany showed that only 22%
of all dialysis patients complained about pruritus at
the time they were questioned [5]. Some of the
representative studies are shown in Table 1.
Interestingly, severe pruritus is very rare in paedia-
tric patients on dialysis. This could be shown by a
systematic review of almost all German paediatric
dialysis centres involving 199 children, where only
9.1% of the children on dialysis complained about
pruritus. Moreover the intensity was not very severe in
the affected patients [11] (Figure 2).
Pathophysiological concepts of uraemic pruritus
In the past 20 years different hypotheses on the patho-
physiology of UP have been generated. The most
prominent concept focused on parathyroid hormone
(PTH) as a culprit compound, because UP seemed to
be most severe in patients with marked hyperpara-
thyroidism and resolved after parathyroidectomy
[12,13]. However, subsequent data could not confirm
this theory [14]. Similarly, the concept of precipitated
calcium phosphate crystals in the setting of elevated
serum calcium and phosphate levels as a responsible
event in UP could not be sustained [15]. Recently
controversy arose as to whether the histamine secreted
by proliferated mast cells might cause UP [16].
However, like the concepts mentioned above, the
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‘histamine story’ ceased because of conflicting results
[10,17,18].
At present, two new concepts with respect to UP
are being discussed and are presented in detail below.
The ‘immuno-hypothesis’
Due to several observations and information from
other studies, there is increasing evidence that UP is
a systemic rather than an isolated skin disease, and
that derangements of the immune system with a pro-
inflammatory pattern may be involved in the patho-
genesis of UP. This hypothesis is supported by several
lines of evidence.
Gilchrest et al. [19] showed that tanning patients
with ultra violet (UV) B light led to relief of UP in
a considerable number of patients. This effect could
be demonstrated even when only half of the body
was irradiated. This observation led to the assumption
that UVB radiation has a systemic effect. Interestingly,
(a) (b)
(c) (d)
Fig. 1. (a–d) Skin affected in patients with uraemic pruritus. (a) Scratches on the arm hosting the fistula. (b) Deep scars on the shoulders and
the back of a female patient on haemodialysis. (c) Prurigo nodularis with excoreations and superinfection on the forearm of a patient on
peritoneal dialysis. (d) Kyrles disease on the back of a patient on haemodialysis.
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UVB exposure was shown to be a pronounced
modulator of Th1 and Th2 lymphocyte differentiation
and to attenuate Th1 expression [20].
Some studies have shown that increasing the dose
of dialysis leads to an improvement in UP [21]. Con-
sequently, the lower incidence of UP over recent
decades has been attributed to the improvement of
dialysis modalities. Increasing concerns about the
adequate dialysis dose and the wide use of KtuV- or
creatinine clearance-guided dialysis regimens might
have contributed to the decreased incidence of UP.
Additionally, dialysis efficacy has increased following
the use of high flux dialysis membranes with larger
surfaces and improved biocompatibility with the
introduction of synthetic fibres, such as polysulfone
or polyacrylnitrile. These new materials activate com-
plement and leukocytes to a much lesser degree
than conventional, less biocompatible materials
such as cuprophane, with less generation of
proinflammatory cytokines [22].
It has been shown that thalidomide and tacrolimus
(as an ointment) are effective in the therapy of UP,
at least to a certain degree [23,24]. Thalidomide, which
is currently used as an immunomodulator to treat
graft-versus-host reactions, suppresses TNF-a produc-
tion and leads to a predominant differentiation of
Th2 lymphocytes with suppression of interleukin-2
(IL-2)-producing Th1 cells [25]. A similar effect can
be observed with tacrolimus, which also suppresses
differentiation of Th1-lymphocytes and ensuing IL-2
production [26].
After kidney transplantation patients almost never
complain about UP as long as immunosuppressive
therapy including cyclosporin is administered, even
when a substantial loss of transplant function has
occurred [27].
Table 1. Prevalence of uraemic pruritus reported in the literature
Study Prevalence % (n) Anamnestic % (n) Statistical
relevance
HD CAPD HD CAPD
Young (1973) 86 (86)
Altmeyer (1982) 78 (28)
Gilchrest (1982) 37 (237) 41 (237)
Bencini (1985) 41 (54) 16 (19) HD)CAPD
Matsumoto (1985) 57 (51)
Parfrey (1988) 49 50 (97) NS
Ba¨ckdahl (1988) 66 (29)
Mettang (1990) 64 (28) 50 (26) 17 (28) 21 (26) NS
Albert (1991) 54 (71) 48 (79) NS
Balaskas (1993) 54 (76) 62 NS
Pauli-Magnus (1999) 22 (378) 43 (44) CAPD)HD
HDshaemodialysis; CAPDscontinuous ambulatory peritoneal dialysis; NSsnot significant.
Fig. 2. Prevalence of uraemic pruritus in children on dialysis (18 years or younger) and in adult dialysis patients (older than 18 years).
The prevalence of uraemic pruritus in children is significantly lower than in adult patients (x2 test; Schwab et al., unpublished data).
1560 T. Mettang et al.
The bottom line of all these observations is that they
point to a substantial role of immunological mechan-
isms in the pathogenesis of UP. Numerous factors are
probably involved, the most likely culprit being IL-2,
which is secreted by activated Th1 lymphocytes. In
coping with this hypothesis, patients receiving IL-2 for
the treatment of malignant disease frequently report
tormenting pruritus [28]. Additionally it has been
shown that intradermally applied IL-2 had a rapid,
although weak pruritogenic effect [29].
To investigate further the hypothesis that IL-2 is
causally linked to UP cytokine and T cell differentia-
tion, patterns should be determined in patients with
and without UP. Additionally, T-cell differentiation
and cytokine pattern should be investigated in children
on dialysis who rarely complain about UP. It has been
reported that older individuals are more likely to
differentiate T helper cells towards Th1 than younger
individuals [30].
Preliminary results of a multicentre study initiated
by our group revealed that patients with UP exhibited
a more pronounced Th1 differentiation than patients
without UP, as determined by measuring intracyto-
plasmatic TNF-a in CD4 cells. These results may
support the hypothesis that an inflammatory state may
convey UP.
The ‘opioid hypothesis’
This pathogenetical concept that changes in the
opiodergic system might be involved in the patho-
physiology of pruritus concept was first developed
for cholestatic pruritus and supported by different lines
of evidence: First, several m-receptor-agonistic drugs
are known to induce pruritus, particularly after central
administration [31,32]. Secondly, it could be demon-
strated in animal studies that cholestasis is associated
with an increased opioidergic tone [33,34]. Thirdly,
administration of opiate antagonists was successful
in the treatment of cholestatic pruritus [35,36]. It was
suggested that cholestatic pruritus may be mediated by
pathological changes in the central nervous system.
This hypothesis was supported by the findings that
a global down-regulation of m-receptors occurred in
the brain of cholestatic rats [37] and that in patients
with chronic cholestasis, an opiate withdrawal-like
syndrome was precipitated by administration of an
oral opiate-antagonist [38].
In 1985 there was a first case report describing suc-
cessful treatment of uraemic pruritus by intravenous
administration of the opiate-antagonist naloxone [39].
The therapeutic use of opiate antagonists in patients
with UP was based on the assumption that endogenous
opiate peptides may also be involved in the pathogen-
esis of UP. A subsequent placebo-controlled clinical
trial by Peer et al. [4] showed that administration of the
oral m-receptor-antagonist naltrexone was associated
with a significant decrease in pruritus perception in all
of the treated patients with severe uraemic pruritus.
However, the number of patients studied was small
and the treatment period (1 week) was short.
When trying to confirm the data from Peer et al. [5]
in a larger cohort (23 patients with moderate to severe
UP) treated for a longer time period (4 weeks), we
failed to obtain any statistically significant response to
naltrexone.
Recently, Kumagai developed the hypothesis that
the activation of k-receptors expressed by dermal cells
and lymphocytes may lead to the suppression of
pruritus sensation. Therefore, when these receptors
are not adequately stimulated or m-receptors are over-
expressed, patients may experience more severe itching.
Consequently the authors are about to test whether
k-receptor-agonists (TRK-820) are able to reduce UP;
their preliminary results appear to be encouraging
(Hiroo Kumagai, personal communication).
Considering the conflicting results mentioned above,
it remains to be established whether the opioidergic
system plays a significant role in the pathophysiology
of uraemic pruritus.
Therapeutic options
As stated above, therapeutic options for UP are sparse.
Most of the success stories turned into reports of
failure. Based on the above-mentioned pathophysio-
logical concepts, we will focus on two recent modal-
ities that were studied extensively by our group:
(i) local treatment with tacrolimus ointment; and
(ii) systemic treatment with naltrexone, a m-receptor
antagonist.
Local treatment with tacrolimus ointment
Due to our inability to help some severely tormented
UP patients, we decided to take a new approach. It
has been shown previously that administering tacro-
limus ointment to the skin of patients with atopic
dermatitis leads to complete or partial resolution of
illness-related symptoms [40]. Three patients on
peritoneal dialysis with severe UP who had frustrat-
ingly been pre-treated with other potentially effective
modalities were recruited. The patients documented
pruritus using a visual analogue scale (VAS), ranging
from 0 to 10, and a detailed pruritus score 3 days prior
to and during the treatment phase. Patients were
instructed to apply a 0.03% tacrolimus ointment twice
daily to the areas most affected by UP for a period of
7 days.
In all three patients, UP could be reduced drama-
tically from the very start of treatment (Figure 3).
Two days after discontinuation of treatment, pruritus
slowly recurred. No side-effects were observed during
or after the treatment period [24].
Tacrolimus ointment seems to be a safe and highly
effective short-term treatment option for patients
suffering from severe UP. However, considering the
potentially carcinogenic effect of systemically admin-
istered tacrolimus, one should be cautious in treating
patients over longer periods of time.
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Systemic treatment with naltrexone,
a m-receptor antagonist
We undertook a placebo-controlled, double-blind
crossover study in patients on haemodialysis or peri-
toneal dialysis with persistent, treatment-resistant
pruritus. Of 422 patients screened between December
1997 and June 1998, 93 suffered from pruritus and
23 were eligible for the study. Patients started either
with a 4-week naltrexone sequence (50 mguday) or
matched placebo. There was a 7-day washout between
the two periods. Pruritus intensity was scored daily
using a VAS, and also weekly using a detailed score
assessing scratching activity, distribution of pruritus,
and frequency of pruritus-related sleep disturbance.
Sixteen of 23 patients completed the study. During
naltrexone therapy, pruritus decreased by 29.2% on
the VAS and by 17.6% on the detailed score. In
comparison, pruritus decreased by 16.9% on the VAS
and by 22.3% during placebo period. The difference
between the naltrexone- and the placebo-treatment
period was not statistically significant (Figure 4). Nine
of 23 patients complained about gastrointestinal
adverse events during the naltrexone period, in com-
parison with only one of 23 patients during the placebo
period (P-0.005).
The results of Peer et al. [4] are in sharp contrast
to the results of our study and cannot be explained
by differences in patient compliance, naltrexone dose
or study design, as both studies were randomized,
placebo-controlled, double-blind crossover trials. As
in the study by Peer et al. [4], subjects included in
our trial had long-lasting, treatment-resistant pruritus
and no evidence of coexisting dermatologic disease.
To exclude factors possibly aggravating uraemic
pruritus, such as inadequate dialysis and anaemia,
only patients who were considered to be well dialysed
and with a haemoglobin level )10 gudl were included
in our trial. We also included patients with evidence of
hyperparathyroidism and hyperphosphataemia, as the
pathogenetic role of these factors in UP is contro-
versial [41]. However, to exclude a relevant influence
of these factors on the effect of naltrexone treatment
we performed a subgroup analysis, examining data
separately for those with hyperparathyroidism anduor
hyperphosphataemia, and those without. Naltrexone
treatment was ineffective in all subgroups.
The pathogenesis of UP may be influenced by
differences in the management of dialysis patients,
and regional differences in life and eating habits in
distinct world regions. In the study by Peer et al. [4],
no details were given on dialysis modalities. Possibly,
the involvement of such additional pathogenetic
factors led to a higher incidence of severe pruritus
and to differences in naltrexone response.
In conclusion, UP remains a clinically important
problem in patients on dialysis. The pathogenesis of
this bothersome and sometimes tormenting symptom
is still obscure. There are hints that derangements
of either the opioidergic anduor the immune system
are involved. A unifying concept would probably sug-
gest that inflammatory stimuli, conveyed by uraemia
anduor dialysis, would lead to both an augmented
differentiation of Th1 lymphocytes and subsequently a
suppression of itch-reducing k-receptors or an increase
of m-receptors in the skin of dialysis patients. However,
this hypothesis remains unproven at present, and
safe and effective therapeutic modalities are lacking.
Immunomodulatory and k-receptor agonistic drugs
may well prove helpful in the most severe cases.
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